Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs.

Francica JR, Zak DE, Linde C, Siena E, Johnson C, Juraska M, Yates NL, Gunn B, De Gregorio E, Flynn BJ, Valiante NM, Malyala P, Barnett SW, Sarkar P, Singh M, Jain S, Ackerman M, Alam M, Ferrari G, Tomaras GD, O'Hagan DT, Aderem A, Alter G, Seder RA.

Blood Adv. 2017 Nov 17;1(25):2329-2342. doi: 10.1182/bloodadvances.2017011411. eCollection 2017 Nov 28. Erratum in: Blood Adv. 2018 Mar 13;2(5):516.

2.

Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines.

Buonsanti C, Balocchi C, Harfouche C, Corrente F, Galli Stampino L, Mancini F, Tontini M, Malyala P, Bufali S, Baudner B, De Gregorio E, Valiante NM, O'Hagan DT, Rappuoli R, D'Oro U.

Sci Rep. 2016 Jul 21;6:29063. doi: 10.1038/srep29063.

3.

Incorporation of Phosphonate into Benzonaphthyridine Toll-like Receptor 7 Agonists for Adsorption to Aluminum Hydroxide.

Cortez A, Li Y, Miller AT, Zhang X, Yue K, Maginnis J, Hampton J, Hall de S, Shapiro M, Nayak B, D'Oro U, Li C, Skibinski D, Mbow ML, Singh M, O'Hagan DT, Cooke MP, Valiante NM, Wu TY.

J Med Chem. 2016 Jun 23;59(12):5868-78. doi: 10.1021/acs.jmedchem.6b00489. Epub 2016 Jun 13.

PMID:
27270029
4.

A new TLR2 agonist promotes cross-presentation by mouse and human antigen presenting cells.

Santone M, Aprea S, Wu TY, Cooke MP, Mbow ML, Valiante NM, Rush JS, Dougan S, Avalos A, Ploegh H, De Gregorio E, Buonsanti C, D'Oro U.

Hum Vaccin Immunother. 2015;11(8):2038-50. doi: 10.1080/21645515.2015.1027467.

5.

Analysis of immunoglobulin transcripts and hypermutation following SHIV(AD8) infection and protein-plus-adjuvant immunization.

Francica JR, Sheng Z, Zhang Z, Nishimura Y, Shingai M, Ramesh A, Keele BF, Schmidt SD, Flynn BJ, Darko S, Lynch RM, Yamamoto T, Matus-Nicodemos R, Wolinsky D; NISC Comparative Sequencing Program, Nason M, Valiante NM, Malyala P, De Gregorio E, Barnett SW, Singh M, O'Hagan DT, Koup RA, Mascola JR, Martin MA, Kepler TB, Douek DC, Shapiro L, Seder RA.

Nat Commun. 2015 Apr 10;6:6565. doi: 10.1038/ncomms7565.

6.

Vaccine composition formulated with a novel TLR7-dependent adjuvant induces high and broad protection against Staphylococcus aureus.

Bagnoli F, Fontana MR, Soldaini E, Mishra RP, Fiaschi L, Cartocci E, Nardi-Dei V, Ruggiero P, Nosari S, De Falco MG, Lofano G, Marchi S, Galletti B, Mariotti P, Bacconi M, Torre A, Maccari S, Scarselli M, Rinaudo CD, Inoshima N, Savino S, Mori E, Rossi-Paccani S, Baudner B, Pallaoro M, Swennen E, Petracca R, Brettoni C, Liberatori S, Norais N, Monaci E, Bubeck Wardenburg J, Schneewind O, O'Hagan DT, Valiante NM, Bensi G, Bertholet S, De Gregorio E, Rappuoli R, Grandi G.

Proc Natl Acad Sci U S A. 2015 Mar 24;112(12):3680-5. doi: 10.1073/pnas.1424924112. Epub 2015 Mar 9.

7.

mTOR inhibition improves immune function in the elderly.

Mannick JB, Del Giudice G, Lattanzi M, Valiante NM, Praestgaard J, Huang B, Lonetto MA, Maecker HT, Kovarik J, Carson S, Glass DJ, Klickstein LB.

Sci Transl Med. 2014 Dec 24;6(268):268ra179. doi: 10.1126/scitranslmed.3009892.

PMID:
25540326
8.

Rational design of small molecules as vaccine adjuvants.

Wu TY, Singh M, Miller AT, De Gregorio E, Doro F, D'Oro U, Skibinski DA, Mbow ML, Bufali S, Herman AE, Cortez A, Li Y, Nayak BP, Tritto E, Filippi CM, Otten GR, Brito LA, Monaci E, Li C, Aprea S, Valentini S, Calabrό S, Laera D, Brunelli B, Caproni E, Malyala P, Panchal RG, Warren TK, Bavari S, O'Hagan DT, Cooke MP, Valiante NM.

Sci Transl Med. 2014 Nov 19;6(263):263ra160. doi: 10.1126/scitranslmed.3009980.

9.

A cationic nanoemulsion for the delivery of next-generation RNA vaccines.

Brito LA, Chan M, Shaw CA, Hekele A, Carsillo T, Schaefer M, Archer J, Seubert A, Otten GR, Beard CW, Dey AK, Lilja A, Valiante NM, Mason PW, Mandl CW, Barnett SW, Dormitzer PR, Ulmer JB, Singh M, O'Hagan DT, Geall AJ.

Mol Ther. 2014 Dec;22(12):2118-29. doi: 10.1038/mt.2014.133. Epub 2014 Jul 16.

10.

Topical SMIP-7.7, a toll-like receptor 7 agonist, protects against genital herpes simplex virus type-2 disease in the guinea pig model of genital herpes.

Bernstein DI, Cardin RD, Bravo FJ, Earwood J, Clark JR, Li Y, Mishra P, Li C, Nayak BP, Miller AT, Wu TY, Cooke MP, Valiante NM.

Antivir Chem Chemother. 2014 Apr 11;23(5):189-96. doi: 10.3851/IMP2499.

PMID:
23232327
11.

The role of non-viral antigens in the cotton rat model of respiratory syncytial virus vaccine-enhanced disease.

Shaw CA, Galarneau JR, Bowenkamp KE, Swanson KA, Palmer GA, Palladino G, Markovits JE, Valiante NM, Dormitzer PR, Otten GR.

Vaccine. 2013 Jan 2;31(2):306-12. doi: 10.1016/j.vaccine.2012.11.006. Epub 2012 Nov 12.

PMID:
23153444
12.

Nonviral delivery of self-amplifying RNA vaccines.

Geall AJ, Verma A, Otten GR, Shaw CA, Hekele A, Banerjee K, Cu Y, Beard CW, Brito LA, Krucker T, O'Hagan DT, Singh M, Mason PW, Valiante NM, Dormitzer PR, Barnett SW, Rappuoli R, Ulmer JB, Mandl CW.

Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14604-9. doi: 10.1073/pnas.1209367109. Epub 2012 Aug 20.

13.

Small molecule Toll-like receptor 7 agonists localize to the MHC class II loading compartment of human plasmacytoid dendritic cells.

Russo C, Cornella-Taracido I, Galli-Stampino L, Jain R, Harrington E, Isome Y, Tavarini S, Sammicheli C, Nuti S, Mbow ML, Valiante NM, Tallarico J, De Gregorio E, Soldaini E.

Blood. 2011 May 26;117(21):5683-91. doi: 10.1182/blood-2010-12-328138. Epub 2011 Apr 12.

14.

A point mutation in the amino terminus of TLR7 abolishes signaling without affecting ligand binding.

Iavarone C, Ramsauer K, Kubarenko AV, Debasitis JC, Leykin I, Weber AN, Siggs OM, Beutler B, Zhang P, Otten G, D'Oro U, Valiante NM, Mbow ML, Visintin A.

J Immunol. 2011 Apr 1;186(7):4213-22. doi: 10.4049/jimmunol.1003585. Epub 2011 Mar 7.

15.

New adjuvants for human vaccines.

Mbow ML, De Gregorio E, Valiante NM, Rappuoli R.

Curr Opin Immunol. 2010 Jun;22(3):411-6. doi: 10.1016/j.coi.2010.04.004. Epub 2010 May 11. Review.

PMID:
20466528
16.

Hepatitis C virions subvert natural killer cell activation to generate a cytokine environment permissive for infection.

Crotta S, Brazzoli M, Piccioli D, Valiante NM, Wack A.

J Hepatol. 2010 Feb;52(2):183-90. doi: 10.1016/j.jhep.2009.11.003. Epub 2009 Dec 16.

PMID:
20015567
17.

Human plasmacytoid dendritic cells are unresponsive to bacterial stimulation and require a novel type of cooperation with myeloid dendritic cells for maturation.

Piccioli D, Sammicheli C, Tavarini S, Nuti S, Frigimelica E, Manetti AG, Nuccitelli A, Aprea S, Valentini S, Borgogni E, Wack A, Valiante NM.

Blood. 2009 Apr 30;113(18):4232-9. doi: 10.1182/blood-2008-10-186890. Epub 2009 Jan 27.

18.

NKp46 and NKG2D recognition of infected dendritic cells is necessary for NK cell activation in the human response to influenza infection.

Draghi M, Pashine A, Sanjanwala B, Gendzekhadze K, Cantoni C, Cosman D, Moretta A, Valiante NM, Parham P.

J Immunol. 2007 Mar 1;178(5):2688-98.

19.

Cytoskeleton rearrangement induced by tetraspanin engagement modulates the activation of T and NK cells.

Crotta S, Ronconi V, Ulivieri C, Baldari CT, Valiante NM, Abrignani S, Wack A.

Eur J Immunol. 2006 Apr;36(4):919-29. Erratum in: Eur J Immunol. 2006 May;36(5):1350. Valiente, Nicholas M [corrected to Valiante, Nicholas M].

20.

Targeting the innate immune response with improved vaccine adjuvants.

Pashine A, Valiante NM, Ulmer JB.

Nat Med. 2005 Apr;11(4 Suppl):S63-8. Review.

PMID:
15812492
21.

Single-cell analysis of the human NK cell response to missing self and its inhibition by HLA class I.

Draghi M, Yawata N, Gleimer M, Yawata M, Valiante NM, Parham P.

Blood. 2005 Mar 1;105(5):2028-35. Epub 2004 Nov 4.

22.

Innate immunity and biodefence vaccines.

Valiante NM, O'Hagan DT, Ulmer JB.

Cell Microbiol. 2003 Nov;5(11):755-60. Review.

PMID:
14531891
23.

Recent advances in the discovery and delivery of vaccine adjuvants.

O'Hagan DT, Valiante NM.

Nat Rev Drug Discov. 2003 Sep;2(9):727-35. Review.

PMID:
12951579
24.

Different profile of CD8+ effector T cells induced in Der p 1-allergic and naïve mice by DNA vaccination.

Draghi M, Jarman ER, Grifantini R, Galli-Stampino L, Lamb JR, Valiante NM, Grandi G.

Eur J Immunol. 2002 Dec;32(12):3720-8.

25.

Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells.

Piccioli D, Sbrana S, Melandri E, Valiante NM.

J Exp Med. 2002 Feb 4;195(3):335-41.

26.

Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein.

Crotta S, Stilla A, Wack A, D'Andrea A, Nuti S, D'Oro U, Mosca M, Filliponi F, Brunetto RM, Bonino F, Abrignani S, Valiante NM.

J Exp Med. 2002 Jan 7;195(1):35-41.

28.

Rapid evolution of NK cell receptor systems demonstrated by comparison of chimpanzees and humans.

Khakoo SI, Rajalingam R, Shum BP, Weidenbach K, Flodin L, Muir DG, Canavez F, Cooper SL, Valiante NM, Lanier LL, Parham P.

Immunity. 2000 Jun;12(6):687-98.

29.

Life, activation and death of intrahepatic lymphocytes in chronic hepatitis C.

Valiante NM, D'Andrea A, Crotta S, Lechner F, Klenerman P, Nuti S, Wack A, Abrignani S.

Immunol Rev. 2000 Apr;174:77-89. Review.

PMID:
10807508
30.

The challenges of vaccinating the very young: lessons from a very old system of host defense.

Valiante NM, Rappuoli R, Insel RA, McInnes P, Hoeveler A.

Vaccine. 1999 Jul 16;17(22):2757-62. No abstract available.

PMID:
10438043
31.

C1.7 antigen expression on CD8+ T cells is activation dependent: increased proportion of C1.7+CD8+ T cells in HIV-1-infected patients with progressing disease.

Peritt D, Sesok-Pizzini DA, Schretzenmair R, Macgregor RR, Valiante NM, Tu X, Trinchieri G, Kamoun M.

J Immunol. 1999 Jun 15;162(12):7563-8.

32.

Dynamics of intra-hepatic lymphocytes in chronic hepatitis C: enrichment for Valpha24+ T cells and rapid elimination of effector cells by apoptosis.

Nuti S, Rosa D, Valiante NM, Saletti G, Caratozzolo M, Dellabona P, Barnaba V, Abrignani S.

Eur J Immunol. 1998 Nov;28(11):3448-55.

33.

Evidence for recombination as a mechanism for KIR diversification.

Shilling HG, Lienert-Weidenbach K, Valiante NM, Uhrberg M, Parham P.

Immunogenetics. 1998 Nov-Dec;48(6):413-6. No abstract available.

PMID:
9799338
34.

The Bw4/Bw6 difference between HLA-B*0802 and HLA-B*0801 changes the peptides endogenously bound and the stimulation of alloreactive T cells.

Arnett KL, Huang W, Valiante NM, Barber LD, Parham P.

Immunogenetics. 1998 Jun;48(1):56-61.

PMID:
9601944
35.

Mismatches for two major and one minor histocompatibility antigen correlate with a patient's rejection of a bone marrow graft from a serologically HLA-identical sibling.

Lienert-Weidenbach K, Valiante NM, Brown C, White C, Johnston-Dow L, McGinnis M, Krausa P, Lakes DM, Wolf JL, Blume KG, Parham P.

Biol Blood Marrow Transplant. 1997 Nov;3(5):255-60.

PMID:
9450920
36.

Natural killer cells, HLA class I molecules, and marrow transplantation.

Valiante NM, Parham P.

Biol Blood Marrow Transplant. 1997 Nov;3(5):229-35. Review. No abstract available.

PMID:
9450917
37.

Human diversity in killer cell inhibitory receptor genes.

Uhrberg M, Valiante NM, Shum BP, Shilling HG, Lienert-Weidenbach K, Corliss B, Tyan D, Lanier LL, Parham P.

Immunity. 1997 Dec;7(6):753-63.

38.

Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors.

Valiante NM, Uhrberg M, Shilling HG, Lienert-Weidenbach K, Arnett KL, D'Andrea A, Phillips JH, Lanier LL, Parham P.

Immunity. 1997 Dec;7(6):739-51.

39.

Natural inactivation of a common HLA allele (A*2402) has occurred on at least three separate occasions.

Magor KE, Taylor EJ, Shen SY, Martinez-Naves E, Valiante NM, Wells RS, Gumperz JE, Adams EJ, Little AM, Williams F, Middleton D, Gao X, McCluskey J, Parham P, Lienert-Weidenbach K.

J Immunol. 1997 Jun 1;158(11):5242-50.

PMID:
9164942
40.

Conserved and variable residues within the Bw4 motif of HLA-B make separable contributions to recognition by the NKB1 killer cell-inhibitory receptor.

Gumperz JE, Barber LD, Valiante NM, Percival L, Phillips JH, Lanier LL, Parham P.

J Immunol. 1997 Jun 1;158(11):5237-41.

PMID:
9164941
41.

Killer cell receptors: keeping pace with MHC class I evolution.

Valiante NM, Lienert K, Shilling HG, Smits BJ, Parham P.

Immunol Rev. 1997 Feb;155:155-64. Review.

PMID:
9059891
43.

The inter-locus recombinant HLA-B*4601 has high selectivity in peptide binding and functions characteristic of HLA-C.

Barber LD, Percival L, Valiante NM, Chen L, Lee C, Gumperz JE, Phillips JH, Lanier LL, Bigge JC, Parekh RB, Parham P.

J Exp Med. 1996 Aug 1;184(2):735-40.

45.

NK cells and CTL: opposite sides of the same coin.

Valiante NM, Parham P.

Chem Immunol. 1996;64:146-63. Review. No abstract available.

PMID:
8942078
46.
47.
48.

Enhancing effect of natural killer cell stimulatory factor (NKSF/interleukin-12) on cell-mediated cytotoxicity against tumor-derived and virus-infected cells.

Chehimi J, Valiante NM, D'Andrea A, Rengaraju M, Rosado Z, Kobayashi M, Perussia B, Wolf SF, Starr SE, Trinchieri G.

Eur J Immunol. 1993 Aug;23(8):1826-30.

PMID:
8102101
49.

Producer cells of interleukin-12.

Trinchieri G, Rengaraju M, D'Andrea A, Valiante NM, Kubin M, Aste M, Chehimi J.

Immunol Today. 1993 May;14(5):237-8. No abstract available.

PMID:
8100137
50.

Regulation of hematopoiesis in vitro by alloreactive natural killer cell clones.

Bellone G, Valiante NM, Viale O, Ciccone E, Moretta L, Trinchieri G.

J Exp Med. 1993 Apr 1;177(4):1117-25.

Supplemental Content

Loading ...
Support Center